Truist Financial Corp Has $269,000 Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Truist Financial Corp lessened its position in Inari Medical, Inc. (NASDAQ:NARI) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,270 shares of the company’s stock after selling 338 shares during the quarter. Truist Financial Corp’s holdings in Inari Medical were worth $269,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NARI. R Squared Ltd acquired a new stake in shares of Inari Medical in the fourth quarter valued at about $45,000. KBC Group NV increased its position in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after buying an additional 498 shares during the period. Covestor Ltd lifted its holdings in shares of Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after buying an additional 926 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Inari Medical by 66.8% in the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock valued at $100,000 after acquiring an additional 786 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Inari Medical by 44.2% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,113 shares of the company’s stock valued at $128,000 after acquiring an additional 954 shares during the period. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Stock Performance

NARI stock opened at $79.97 on Thursday. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $79.99. The business’s 50 day moving average is $74.99 and its 200-day moving average is $57.08. The firm has a market cap of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02.

Insider Activity at Inari Medical

In other news, Director William Hoffman sold 60,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the completion of the sale, the director now owns 441,233 shares of the company’s stock, valued at approximately $24,559,028.78. This trade represents a 11.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the completion of the transaction, the chief executive officer now owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This trade represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 263,000 shares of company stock valued at $15,599,470 in the last 90 days. 10.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Oppenheimer assumed coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They set an “outperform” rating and a $75.00 target price for the company. William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. BTIG Research restated a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Finally, Truist Financial raised their price objective on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $68.00.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.